A biotechnology firm focused on developing therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's. Investors monitor Biogen for its pipeline of innovative treatments and its role in the competitive CNS drug market.
2 members of Congress have disclosed 2 trades in Biogen Inc. (BIIB), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2007-06-11 | JANE HARMAN | buy | $50K – $100K |
| 2007-03-08 | CAROLYN MCCARTHY | sell | $663.33 |